I’m not even too sure on the exact science with their platform, but Roche and Merck are in for the research studies involving yeast cells. BD
From the website:
“Adimab's integrated antibody discovery and optimization platform provides unprecedented speed from antigen to purified, full-length human IgGs. 
Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most aggressive standards for affinity, epitope coverage, species cross-reactivity and expressability. Adimab enables its partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements.”
“Whereas human B-cell/hybridoma cell lines take days to generate a measurable readout, Adimab’s fully human, yeast-based platform provides a readout in hours resulting in a vastly accelerated discovery and maturation cycles.”
Adimab’s technology, developed by scientists at Dartmouth and M.I.T., can help pharmaceutical companies find effective monoclonal antibodies, which are genetically engineered versions of proteins the body makes to latch onto invading pathogens. Some of the most successful drugs, like the cancer drug Avastin and the rheumatoid arthritis drug Humira, are monoclonal antibodies.
Two big drug companies, Roche and Merck, have already signed up to use Adimab’s technology, which involves creating a huge library of candidate antibodies in yeast cells.
0 comments :
Post a Comment